My previous post on the Myriad gene patent decision has resulted in one of the most useful and enjoyable comment threads in the history of this blog.
The debate revolves around a single, central question: while it's clear that the loss of gene-based patent protection (should the current decision be upheld by the Supreme Court) will be beneficial for companies and academic labs seeking to develop multi-gene tests - extending up to whole-genome sequencing - will these benefits come at a disastrous cost to the field as a whole by eroding financial incentives for innovation?
This outcome is being waved around by various people (Nature News' piece on the patent decision is sub-titled "Court ruling may spell bad news for biotech industry"). However, several commenters in the thread make devastating arguments against this claim, and I'm being swayed towards the idea that the concerns about stifling of innovation are overblown.
Many thanks to Dan Vorhaus, Linda Avey, Keith Grimaldi, p-ter and others for their civil and constructive comments.
- Log in to post comments
More like this
One of the major potential stumbling blocks for the field of genome-based diagnostics - particularly as we begin to move into the whole-genome sequencing era - is the unresolved issue of gene patents.
Currently somewhere in the order of 20% of the protein-coding genes in the human genome are…
I'm slowly catching up on genomics news from the last week - this story in particular has been getting a lot of press.
The executive summary: Jay Flatley, CEO of genomic technology manufacturer Illumina, predicts that whole-genome sequencing of newborns will become routine within a decade.
Flatley…
Tomorrow morning, a three-judge panel of the Court of Appeals for the Federal Circuit will hear arguments in the appeal of Association for Molecular Pathology v. U.S. Patent and Trademark Office - better known as the Myriad gene patent case.* It has the patent and genetic blogospheres in a bit of…
Some interesting news about the breast cancer patent lawsuit I wrote about for Slate's Double X Magazine a few months ago: A federal district court has just agreed to hear the case. When the lawsuit was first filed, many legal experts I talked to said they were sure the case would get thrown out…
This will be a net positive, a big net positive. Giving any entity monopoly control over something with as trivial an intellectual effort as simply sequencing it is nonsense.
http://www.youtube.com/watch?v=BNjcuZ-LiSY
Cake, please.